Kezar Divests Sec61 Program to Refocus on Core Pipeline

Kezar Life Sciences ( (KZR) ) has provided an announcement.

On March 6, 2026, Kezar Life Sciences agreed to sell its Sec61-based discovery and development program, including preclinical candidate KZR-261, to Enodia Therapeutics in an asset deal under which Enodia assumed related liabilities but did not acquire Kezar’s zetomipzomib program or other core assets. Kezar received $800,000 at closing, is due a further $200,000 tied to inventory transfer timing, and is eligible for up to $127 million in development, regulatory and commercial milestones plus single-digit tiered royalties on future product sales.

The agreement, announced publicly in a joint press release on March 12, 2026, strengthens Enodia’s Sec61 portfolio and integrates Kezar’s extensive preclinical datasets into Enodia’s targeted protein degradation platform, potentially accelerating its Sec61-driven pipeline in inflammation, immunology and oncology. For Kezar, divesting a decade-long Sec61 research effort while retaining economic participation allows renewed strategic focus on its immune-mediated disease programs, notably zetomipzomib, without transferring employees, cash or core operating assets.

The most recent analyst rating on (KZR) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Kezar Life Sciences stock, see the KZR Stock Forecast page.

Spark’s Take on KZR Stock

According to Spark, TipRanks’ AI Analyst, KZR is a Neutral.

The score is held down primarily by weak financial performance (no recent revenue, persistent large losses, and heavy cash burn), with additional pressure from negative corporate developments around regulatory setbacks and restructuring. These risks are partly balanced by improving technical momentum and a low-leverage balance sheet, while valuation support is limited given ongoing losses and no dividend.

To see Spark’s full report on KZR stock, click here.

More about Kezar Life Sciences

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics for unmet needs in immune-mediated diseases. Its lead candidate, zetomipzomib, is a selective immunoproteasome inhibitor currently being evaluated for autoimmune hepatitis and has potential applications across multiple chronic immune-mediated conditions.

Enodia Therapeutics is a biotechnology company focused on small-molecule therapies that drive targeted protein degradation at the point of synthesis via Sec61 translocon modulation. Built on research from the Institut Pasteur and Argobio, its pipeline initially targets inflammation, immunology and oncology, with additional opportunities in virology.

Average Trading Volume: 39,208

Technical Sentiment Signal: Hold

Current Market Cap: $51.41M

See more insights into KZR stock on TipRanks’ Stock Analysis page.